Supply Chain Solutions For The Growing Orphan Drug Market

Orphan drug development has seen significant growth in recent years, with many large pharmaceutical companies shifting focus from traditional, mass market drugs to treatments for rare diseases. Orphan drugs are defined by the U.S. Orphan Drug Act of 1983 (ODA) as a drug intended for the safe and effective treatment, diagnosis or prevention of rare diseases/disorders that affect fewer than 200,000 people in the U.S., or that affect more than 200,000 persons but are not expected to recover the costs of developing and marketing a treatment drug.